Engen Inc., a biotechnology company, announced that Dr. Eric Hsu, senior director of preclinical research, is scheduled to present the latest data on the use of proprietary technology Engen concentrate delivery of interleukin-10 in the colon for the treatment of inflammatory bowel disease with the Canadian Association of Gastroenterology Annual Scientific Conference in Toronto. Selected as ‘Poster of Distinction,’ Dr. The poster session will be held 3:15 to 6:00 p.m. February 28, 2010 in Fairmount Royal York Hotel, Ballroom Salon & B.IBD is an autoimmune disease whose etiology is unknown. In Canada, IBD is common with more than 200,000 Canadians affected and 9000 new cases diagnosed each year. The economic impact for IBD in Canada is about $ 1.8 billion a year, including direct costs, not direct.
The research team, jointly led by White and Kenton Swartz of ‘National Institute of Neurological Disorders and Disease , also includes scientists from the University of Missouri, the National Institute of Alcohol Abuse and Alcoholism and the NCNR.
Funding for the study were provided by the National Science Foundation, the National Institute of General Medical Sciences and NINDS.